QuickView: Focused on clinical cell therapies
After raising over $25m through equity/warrant financings and extending the debt maturity, Cytori can focus on its late-stage R&D programmes. Its ADRC therapy clinical trials in scleroderma and knee osteoarthritis aim to show that the implantation of patient-derived cells can improve functional outcomes.Cytori Therapeutics develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. The company's pipeline is targeted for impaired hand function in scleroderma, osteoarthritis of the knee, stress urinary incontinence, and deep thermaL. Cytori Cell Therapy platform is based on the scientific discovery that the human adipose or fat tissue compartment is a source of mixed population of stem, progenitor and regenerative cells that may hold substantial promise in the treatment of numerous diseases. Cytori Nanomedicine platform features protein-stabilized liposomal nanoparticle technology for drug encapsulation.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.